心房颤动患者经导管左心耳封堵与口服抗凝比较的系统综述与荟萃分析
该系统综述与荟萃分析纳入 8 项随机试验共 7434 例卒中高风险心房颤动患者,比较经导管左心耳封堵与口服抗凝的长期疗效与安全性。加权平均随访 37.9 个月后,两组任何类型卒中与大出血发生率相近,但左心耳封堵的缺血性卒中风险更高,非操作相关大出血风险更低。结果不支持将左心耳封堵作为中高卒中风险房颤患者的一线卒中预防策略。
要点
- 左心耳封堵与口服抗凝的长期任何类型卒中和大出血发生率无显著差异。
- 左心耳封堵较口服抗凝增加缺血性卒中风险,降低非操作相关大出血风险。
- 现有证据不支持左心耳封堵作为中高卒中风险房颤患者的一线策略。
核心结论
- 在长期随访中,经导管左心耳封堵与口服抗凝相比,任何类型卒中和大出血发生率相近。
- 左心耳封堵增加缺血性卒中风险,降低非操作相关大出血风险。
- 研究结果不支持将左心耳封堵作为中高卒中风险房颤患者的一线卒中预防策略。
研究设计与样本
- 该研究为系统综述与荟萃分析,检索 PubMed、Cochrane Central 和 Web of Science 截至 2026 年 3 月。
- 同时检索主要心脏病学会网站、新闻媒体及合格研究的参考文献列表。
- 纳入随机分配至经导管左心耳封堵或口服抗凝并报告至少一项相关结局的房颤患者研究。
- 共纳入 8 项试验,总计 7434 例患者,采用频率学派随机效应模型合并发生率比(IRR)。
主要发现
- 加权平均随访 37.9 个月后,两组任何类型卒中无显著差异(IRR 1.08;95% CI 0.82-1.41)。
- 两组大出血无显著差异(IRR 0.96;95% CI 0.81-1.14)。
- 与口服抗凝相比,左心耳封堵的缺血性卒中风险更高(IRR 1.34;95% CI 1.01-1.77)。
- 左心耳封堵的非操作相关大出血风险更低(IRR 0.73;95% CI 0.58-0.92)。
- 每 1000 例患者的操作相关事件为:卒中 5 例、出血 9 例、死亡 1 例、器械栓塞 5 例、心包积液 9 例。
临床怎么用
- 对于中高卒中风险的心房颤动患者,不应将左心耳封堵常规作为一线卒中预防策略。
- 左心耳封堵可考虑用于口服抗凝出血风险过高或不耐受的患者,但需权衡缺血性卒中增加的潜在风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with atrial fibrillation (AF), oral anticoagulation (OAC) is the gold standard for preventing ischemic stroke, at the expense of a higher risk of bleeding. Catheter-based left atrial appendage closure (LAAC) has been proposed as an alternative strategy to prevent stroke, but the efficacy and safety compared to OAC are uncertain. OBJECTIVE: To evaluate the efficacy and safety of catheter-based LAAC compared to OAC in patients with AF at high risk of stroke. DATA SOURCES: PubMed, Cochrane Central, and Web of Science were screened up to March 2026. The websites of leading cardiology societies, news outlets, and reference lists of each eligible study were also inspected. STUDY SELECTION: Studies enrolling patients with AF randomly assigned to catheter-based LAAC or OAC and reporting at least 1 outcome of interest were included. DATA EXTRACTION AND SYNTHESIS: Two investigators independently extracted data of interest and assessed data quality. Catheter-based LAAC vs OAC comparisons were pooled as incidence rate ratios (IRRs) using a frequentist random-effect model. MAIN OUTCOMES AND MEASURES: Primary and coprimary outcomes were long-term stroke and major bleeding. Secondary outcomes included the composite of cardiovascular death, stroke, or systemic embolism, all-cause death, the single components of the composite end point, ischemic stroke, hemorrhagic stroke, and nonprocedural major bleeding. Periprocedural events (ie, stroke, major bleeding, death, device embolization, and pericardial effusion) were also combined. RESULTS: Eight trials (7434 patients) were included in the meta-analysis. After a weighted mean follow-up of 37.9 months, no significant differences were detected for stroke (IRR, 1.08; 95% CI, 0.82-1.41) and major bleeding (IRR, 0.96; 95% CI, 0.81-1.14). However, catheter-based LAAC was associated with a higher risk of ischemic stroke (IRR, 1.34; 95% CI, 1.01-1.77) and a lower risk of nonprocedural major bleeding (IRR, 0.73; 95% CI, 0.58-0.92) compared with OAC. Periprocedural events per 1000 patients were 5 strokes, 9 episodes of bleeding, 1 death, 5 episodes of device embolization, and 9 pericardial effusions. CONCLUSIONS AND RELEVANCE: In patients with AF, at long-term follow-up, transcatheter LAAC was associated with similar rates of any type of stroke and major bleeding compared with OAC, while increasing the risk of ischemic stroke and lowering the risk of nonprocedure-related major bleeding. These findings do not support the routine use of LAAC as a first-line strategy for stroke prevention in patients with AF at moderate to high risk of stroke.
引用
- Laudani, Bujak, Giacoppo, et al. Catheter-Based Left Atrial Appendage Closure vs Oral Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2026. PMID: 42646743. doi:10.1001/jamacardio.2026.2640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。